Dendritic cell subsets in cancer immunity and tumor antigen sensing

A Del Prete, V Salvi, A Soriani, M Laffranchi… - Cellular & molecular …, 2023 - nature.com
Dendritic cells (DCs) exhibit a specialized antigen-presenting function and play crucial roles
in both innate and adaptive immune responses. Due to their ability to cross-present tumor …

Biomedicine meets Fenton chemistry

Z Tang, P Zhao, H Wang, Y Liu, W Bu - Chemical reviews, 2021 - ACS Publications
Since the first connection between Fenton chemistry and biomedicine, numerous studies
have been presented in this field. Comprehensive presentation of the guidance from Fenton …

Cancer vaccines: Building a bridge over troubled waters

MLC Sellars, CJ Wu, EF Fritsch - Cell, 2022 - cell.com
Cancer vaccines aim to direct the immune system to eradicate cancer cells. Here we review
the essential immunologic concepts underpinning natural immunity and highlight the …

Recent development of gold (I) and gold (III) complexes as therapeutic agents for cancer diseases

Y Lu, X Ma, X Chang, Z Liang, L Lv, M Shan… - Chemical Society …, 2022 - pubs.rsc.org
Metal complexes have demonstrated significant antitumor activities and platinum complexes
are well established in the clinical application of cancer chemotherapy. However, the …

The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy

D Bruni, HK Angell, J Galon - Nature Reviews Cancer, 2020 - nature.com
Abstract The international American Joint Committee on Cancer/Union for International
Cancer Control (AJCC/UICC) tumour-node-metastasis (TNM) staging system provides the …

Next generation gold drugs and probes: chemistry and biomedical applications

RT Mertens, S Gukathasan, AS Arojojoye… - Chemical …, 2023 - ACS Publications
The gold drugs, gold sodium thiomalate (Myocrisin), aurothioglucose (Solganal), and the
orally administered auranofin (Ridaura), are utilized in modern medicine for the treatment of …

Resistance mechanisms of anti-PD1/PDL1 therapy in solid tumors

Q Lei, D Wang, K Sun, L Wang… - Frontiers in cell and …, 2020 - frontiersin.org
In cancer-immunity cycle, the immune checkpoint PD1 and its ligand PDL1 act as
accomplices to help tumors resist to immunity-induced apoptosis and promote tumor …

Immunogenic cell death in cancer therapy: Present and emerging inducers

J Zhou, G Wang, Y Chen, H Wang… - Journal of cellular and …, 2019 - Wiley Online Library
In the tumour microenvironment (TME), immunogenic cell death (ICD) plays a major role in
stimulating the dysfunctional antitumour immune system. Chronic exposure of damage …

Mechanisms of resistance to immune checkpoint blockade: why does checkpoint inhibitor immunotherapy not work for all patients?

CM Fares, EM Van Allen, CG Drake… - American Society of …, 2019 - ascopubs.org
The emergence of immune checkpoint blockade therapies over the last decade has
transformed cancer treatment in a wide range of tumor types. Unprecedented and durable …

Tumor microenvironment: Challenges and opportunities in targeting metastasis of triple negative breast cancer

KGK Deepak, R Vempati, GP Nagaraju… - Pharmacological …, 2020 - Elsevier
Triple negative breast cancer (TNBC) is most aggressive subtype of breast cancers with high
probability of metastasis as well as lack of specific targets and targeted therapeutics. TNBC …